ELTX Share Price Performance
US$8.19
3.12 (61.54%)
91.4% undervalued intrinsic discount
US$95.00
Fair Value
Price US$8.19
Coward_Nutlick US$95.00
Fair ValueUS$95.00
Share Pricen/a
Elicio Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
ELTX Community Narratives
CO
Fair Value US$95 91.4% undervalued intrinsic discount
Very Bullish
2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
Very Bullish
98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more
139
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
CO
US$95
91.4% undervalued intrinsic discount
Coward_Nutlick's Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2030
US$0
Trending Discussion
Recently Updated Narratives
CO
Very Bullish
Fair Value: US$95 91.4% undervalued intrinsic discount
6 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Elicio Therapeutics, Inc. Key Details
About ELTX
- Founded
- n/a
- Employees
- 32
- CEO
- WebsiteView website
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
